Business Case

Characterized the KOL and CoE Landscape for a pediatric dysregulation syndrome to support pre-commercialization planning at a mid-sized pharmaceutical company

A mid-sized Italian pharmaceutical company was planning the clinical development of a therapy for pediatric dysregulation syndrome and needed assistance understanding the setting and providers of care. LSC stepped in to characterize the KOL and CoE landscape, providing our client with a comprehensive overview to inform their pre-commercialization strategy, ensuring a tailored and informed approach to their treatment launch.